News

Three agreements on the implementation of investment projects worth more than 20 billion rubles were signed at XXVI St. Petersburg International Economic Forum between Kaluga Region and Pharmasintez-Kaluga LLC.
On June 14, the relevant documents were signed by Vladislav Shapsha, governor of Kaluga region, and Oleg Astafurov, Vice President for Government Relations at Pharmasintez Group.

3 investment agreements signed within the framework of SPIEF-2023 launch a global project:
— Agreement of Intent to implement projects in the Vorotynsk Industrial Park.

At the site, the company will launch its largest complex for the production of active pharmaceutical substances and finished dosage forms. 19 production and auxiliary facilities will be built. Investments in the project will exceed 20 billion rubles. 2,000 jobs will be created by 2032.
At the 1st stage, it is planned to build 2 production buildings. Pre-design work is currently underway.
With relation  to these projects, following cooperation agreements were signed at SPIEF:
— on the construction of a plant for the production of active pharmaceutical substances by 2026. 4 billion rubles will be invested in the project. 160 jobs will be created.

The plant will produce substances of both the general therapeutic spectrum and oncological (about 60 types of each), which will almost completely cover the needs of Russian healthcare, and will also be exported abroad.
At the moment Pharmasintez pharmaceutical substances are produced by the Bratskkhimsintez plant. Their volume is about 120 tons per year. The enterprise in Kaluga is planned to produce up to 1000 tons of substances per year.
— on the launch of an enterprise for the production of finished dosage forms by 2026. About 3.5 billion rubles will be invested in the project. 200 new jobs will be created at the new enterprise.
Governor Vladislav Shapsha stressed: "This is an important economic event for our region and for the whole country. Russian President Vladimir Putin has clearly outlined the tasks: to increase the production of Russian substances, increase the share of Russian drugs in the domestic market, strengthen national independence from foreign suppliers. The pharmaceutical cluster in Kaluga Region consists of about 70 enterprises that produce more than 230 types of finished medicines. And today it has been replenished with the largest resident. I am grateful to Vikram Punia, President of Pharmasintez Group, for the decision to place production in Kaluga Region."
Oleg Astafurov, Vice President for Government Relations at Pharmasintez Group, stressed: "Pharmasintez has been and remains one of the largest investors in the Russian pharmaceutical market. Pharmasintez Group strives to provide the population of the country with high-quality and affordable generics, for these purposes, the company is expanding the cycle of technological alterations towards the production of active pharmaceutical substances, which significantly reduces the cost of pharmaceutical products production, and therefore ensures its higher availability for the healthcare system of the Russian Federation and the population of the country."

For reference:
Pharmasintez Group is one of the largest domestic manufacturers of socially significant medicines: antitumor, hormonal, antiviral, anti-tuberculosis, antidiabetic, cardiological, radiopaque, antibiotics, vaccines and pharmaceutical substances. The product portfolio includes over 300 names of medicines and over 80 names of pharmaceutical substances. More than 80% of the manufactured drugs are included in the list of vital and essential medicines.
Pharmasintez Group was founded in 1997. Production facilities are represented by five high-tech factories in the cities of Ussuriysk, Irkutsk, Bratsk, Tyumen, St. Petersburg. The annual output exceeds 87 million packages. By the end of 2022, the consolidated revenue of the Group amounted to 43 billion rubles. The number of employees exceeds 4,000 people.
The company is the largest investor in the Russian pharmaceutical industry. To date, the company has invested over 23 billion rubles in the development of production facilities and new developments.